ASI disposable autoinjector project to enter second phase
Drug delivery and orthopaedic devices company The Medical House (TMH) has been commissioned by an undisclosed European Government Agency to enter into a second phase of development for a system based on its ASI disposable autoinjector technology for the emergency administration of specific pharmaceutical compounds.
Drug delivery and orthopaedic devices company The Medical House (TMH) has been commissioned by an undisclosed European Government Agency to enter into a second phase of development for a system based on its ASI disposable autoinjector technology for the emergency administration of specific pharmaceutical compounds.
The agreement involves TMH developing and manufacturing devices, according to defined operational and functional requirements, for technical assessment, over an anticipated 12 month project duration. Under the terms of the agreement, TMH will receive up to £1m, subject to achieving agreed milestones, in relation to the cost of the project including associated design and development activities.
'This project represents our largest development project to date and provides further high quality endorsement of the strength and flexibility of our ASI autoinjector technology,' said Ian Townsend, executive chairman, The Medical House. The ASI's particular strengths relate to simplicity of the underlying technology and its ease of use, which make the ASI ideally suited to customisation for specific client requirements, especially so in the case of emergency injection..'
The agreement involves TMH developing and manufacturing devices, according to defined operational and functional requirements, for technical assessment, over an anticipated 12 month project duration. Under the terms of the agreement, TMH will receive up to £1m, subject to achieving agreed milestones, in relation to the cost of the project including associated design and development activities.
'This project represents our largest development project to date and provides further high quality endorsement of the strength and flexibility of our ASI autoinjector technology,' said Ian Townsend, executive chairman, The Medical House. The ASI's particular strengths relate to simplicity of the underlying technology and its ease of use, which make the ASI ideally suited to customisation for specific client requirements, especially so in the case of emergency injection.'